PYXS
Pyxis Oncology Inc.
$3.56
+$0.14(+4.09%)
58
Overall
60
Value
75
Tech
39
Quality
Market Cap
$139.54M
Volume
612.80K
52W Range
$0.83 - $5.39
Target Price
$6.00
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | $-6.2M | -- | $1.8M | $19.1M | ||
| Total Revenue | $-6.2M | -- | $1.8M | $16.1M | ||
| COST OF GOODS SOLD | ||||||
| Cost of Revenue | -- | -- | -- | $475.0K | ||
| GROSS PROFIT | ||||||
| Gross Profit | $-6.2M | -- | $1.8M | $15.7M | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $-69.7M | $123.5M | $82.2M | $84.2M | ||
| Research & Development | $51.1M | $86.1M | $49.6M | $58.7M | ||
| Research Expense | $51.1M | $86.1M | $49.6M | $58.7M | ||
| Selling, General & Administrative | $18.7M | $37.4M | $32.6M | $25.4M | ||
| General & Administrative Expenses | $18.7M | $37.4M | $32.6M | $25.4M | ||
| Salaries & Wages | $-6.4M | -- | $16.9M | $12.9M | ||
| Depreciation & Amortization | $-600.0K | $700.0K | $1.8M | $2.0M | ||
| Depreciation & Amortization | $-600.0K | $700.0K | $1.8M | $2.0M | ||
| Amortization | -- | -- | $24.3M | $2.6M | ||
| Other Operating Expenses | $-650.0K | $3.8M | $3.9M | $4.4M | ||
| OPERATING INCOME | ||||||
| Operating income | $-75.9M | $-123.5M | $-82.2M | $-89.5M | ||
| EBITDA | $-75.4M | $-122.8M | $-71.9M | $-76.5M | ||
| NON-OPERATING ITEMS | ||||||
| Intinc | $204.0K | $2.8M | $1.8M | $930.0K | ||
| Net Non-Operating Interest Income/Expense | $204.0K | $2.8M | $1.8M | $930.0K | ||
| Gain on Sale of Securities | -- | $2.8M | $6.6M | $7.0M | ||
| Other Income/Expense | $231.0K | $-2.8M | $-6.7M | $13.8M | ||
| Other Special Charges | -- | -- | $8.4M | $10.0M | ||
| SPECIAL ITEMS | ||||||
| Other Impairment Of Capital Assets | -- | -- | -- | $21.0M | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-76.0M | $-123.5M | $-73.8M | $-79.5M | ||
| Pre-Tax Income | $-76.0M | $-120.7M | $-73.8M | $-79.5M | ||
| INCOME TAX | ||||||
| Tax Provision | -- | -- | -- | $-2.2M | ||
| NET INCOME | ||||||
| Net Income | $-76.0M | $-120.7M | $-73.8M | $-77.3M | ||
| Net Income (Continuing Operations) | $-76.0M | $-120.7M | $-73.8M | $-77.3M | ||
| Net Income (Discontinued Operations) | $-76.0M | $-120.7M | $-73.8M | $-77.3M | ||
| Net Income (Common Stockholders) | $-76.0M | $-120.7M | $-73.8M | $-77.3M | ||
| Normalized Income | -- | -- | -- | $-60.7M | ||
| TOTALS | ||||||
| Total Expenses | $-69.7M | $123.5M | $82.2M | $84.6M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $8.5M | $33.0M | $39.9M | $58.4M | ||
| Average Shares Outstanding (Diluted) | $8.5M | $33.0M | $39.9M | $58.4M | ||
| Shares Outstanding | $32.8M | $37.0M | $58.1M | $61.6M | ||
| Basic EPS | -- | $-3.65 | $-1.85 | $-1.32 | ||
| Basic EPS (Continuing Operations) | -- | $-3.65 | $-1.85 | $-1.32 | ||
| Diluted EPS | $-8.95 | $-3.65 | $-1.85 | $-1.32 | ||
| Diluted EPS (Continuing Operations) | -- | $-3.65 | $-1.85 | $-1.32 | ||
| OTHER METRICS | ||||||
| Earnings from equity interest | $-231.0K | -- | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | $-231.0K | -- | -- | -- | ||
| Gain On Sale Of P P E | $-6.2M | -- | -- | -- | ||
| Other Gand A | $18.7M | $37.4M | $32.6M | $25.4M | ||
| Rent And Landing Fees | $18.7M | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PYXS | $3.56 | +4.1% | 612.80K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |